Matinas BioPharma Holdings, Inc. announced that its Board of Directors approved a one-for-fifteen (1:15) reverse stock split of its common stock. The action was authorized by shareholders in June 2025 and is intended to help maintain compliance with NYSE American listing requirements. The split becomes effective at 12:01 a.m. Eastern Time on September 28, 2026, with trading resuming on the same date under the existing symbol MTNB. Fractional shares will be cashed out rather than issued. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases and cancer.
